References
- Rostoker G. Schönlein-Henoch purpura in children and adults. BioDrugs 2001; 15(2)99–138
- Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D, et al. Henoch-Schönlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol 2002; 13: 1271–8
- Chan TM, Tse KC, Tang CSO, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076–84
- Bergner R, Hoffmann M, Brass H, Uppenkamp M. Therapy of IgA nephropathy with mycophenolate mofetil—report of 3 cases. Clin Nephrol 2004; 61(3)207–12
- Choi MJ, Eustace JA, Gimenez LF, Atta MG, Scheel PJ, Sothinathan R, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61: 1098–114
- Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349(9054)774
- Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, et al. Mycophenolate mofetil in IgA nephropathy: result of a 3 year prospective placebo-controlled randomized study. Kidney Int 2004; 65: 1842–9
- Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant 2005; 20: 2139–45
- Tang S, Leung JC, Chan LY, Lui YH, Tang CS, Kan CH, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68(2)802–12